An MSI Tumor Specific Frameshift Mutation in a Coding Microsatellite of MSH3 Encodes for HLA-A0201-Restricted CD8+ Cytotoxic T Cell Epitopes

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Garbe, Yvette ^a   Maletzki, Claudia ^b   Linnebacher, Michael ^b  

^a OncoRay National Center for Radiation Research in Oncology   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GRANZYME B; HLA A ANTIGEN; HLA A0201 ANTIGEN; PROTEIN MSH3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; EPITOPE; HLA A*02:01 ANTIGEN; HLA A2 ANTIGEN; HLA-A*02:01 ANTIGEN; MICROSATELLITE DNA; MSH3 PROTEIN, HUMAN;

ARTICLE; CARCINOMA CELL; CD8+ T LYMPHOCYTE; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; FRAMESHIFT MUTATION; GENE FUNCTION; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MICROSATELLITE INSTABILITY; MSH3 GENE; NUCLEOTIDE SEQUENCE; ONCOGENE; TARGET CELL; UPREGULATION; AMINO ACID SEQUENCE; ANIMAL; CELL CLONE; CELL STRAIN 3T3; CHEMISTRY; COLORECTAL TUMOR; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; GENETICS; IMMUNOLOGY; MOUSE; PATHOLOGY; TH2 CELL; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CLONE CELLS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA-BINDING PROTEINS; EPITOPES, T-LYMPHOCYTE; FRAMESHIFT MUTATION; HLA-A2 ANTIGEN; HUMANS; MICE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; NIH 3T3 CELLS; T-LYMPHOCYTES, CYTOTOXIC; TH2 CELLS;

EID: 84858784003     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026517     Document Type: Article

References (22)

1. Meijer TW, Hoogerbrugge N, Nagengast FM, Ligtenberg MJ, van Krieken JH, (2009) In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response. Histopathology 55: 414-422.
2. Drescher KM, Sharma P, Lynch HT, (2010) Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients. Clin Dev Immunol 2010: 170432.
3. Deschoolmeester V, Baay M, Van Marck E, Weyler J, Vermeulen P, et al.(2010) Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients. BMC Immunol 11: 19.
4. Damia G, D'Incalci M, (2010) Genetic instability influences drug response in cancer cells. Curr Drug Targets 11: 1317-1324.
5. Woerner SM, Gebert J, Yuan YP, Sutter C, Ridder R, et al.(2001) Systematic identification of genes with coding microsatellites mutated in DNA mismatch repair-deficient cancer cells. Int J Cancer 93: 12-19.
6. Woerner SM, Kloor M, Schwitalle Y, Youmans H, Doeberitz MK, et al.(2007) The putative tumor suppressor AIM2 is frequently affected by different genetic alterations in microsatellite unstable colon cancers. Genes Chromosomes Cancer 46: 1080-1089.
7. Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, et al.(2001) Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 93: 6-11.
8. Ripberger E, Linnebacher M, Schwitalle Y, Gebert J, von Knebel Doeberitz M, (2003) Identification of an HLA-A0201-restricted CTL epitope generated by a tumor-specific frameshift mutation in a coding microsatellite of the OGT gene. J Clin Immunol 23: 415-423.
9. Schwitalle Y, Linnebacher M, Ripberger E, Gebert J, von Knebel Doeberitz M, (2004) Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells. Cancer Immun 4: 14.
10. Linnebacher M, Wienck A, Boeck I, Klar E, (2010) Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO). J Biomed Biotechnol 2010: 841451.
11. Saeterdal I, Gjertsen MK, Straten P, Eriksen JA, Gaudernack G, (2001) A TGFbetaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8+ T cells. Cancer Immunol Immunother 50: 469-476.
12. Saeterdal I, Bjørheim J, Lislerud K, Gjertsen MK, Bukholm IK, et al.(2001) Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer. Proc Natl Acad Sci U S A 98: 13255-13260.
13. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, et al.(2008) Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 134: 988-997.
14. Woerner SM, Yuan YP, Benner A, Korff S, von Knebel Doeberitz M, et al.(2010) SelTarbase, a database of human mononucleotide-microsatellite mutations and their potential impact to tumorigenesis and immunology. Nucleic Acids Res 38: 682-689.
15. Duraturo F, Liccardo R, Cavallo A, De Rosa M, Grosso M, et al.(2010) Association of low risk MSH3 and MSH2 variant alleles with Lynch syndrome: probability of synergistic effects. Int J Cancer 129: 1643-1650.
16. Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboüé R, et al.(2009) Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol 22: 1186-1195.
17. Plaschke J, Krüger S, Jeske B, Theissig F, Kreuz FR, et al.(2004) Loss of MSH3 protein expression is frequent in MLH1-deficient colorectal cancer and is associated with disease progression. Cancer Res 64: 864-870.
18. Yashiro M, Hirakawa K, Boland CR, (2010) Mutations in TGFbeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability. BMC Cancer 10: 303.
19. Takahashi M, Koi M, Balaguer F, Boland CR, Goel A, (2011) MSH3 Mediates Sensitization of Colorectal Cancer Cells to Cisplatin, Oxaliplatin, and a Poly(ADP-ribose) Polymerase Inhibitor. J Biol Chem 286: 12157-12165.
20. Haugen AC, Goel A, Yamada K, Marra G, Nguyen TP, et al.(2008) Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res 68: 8465-8472.
21. Williams DS, Bird MJ, Jorissen RN, Yu YL, Walker F, et al.(2010) Nonsense mediated decay resistant mutations are a source of expressed mutant proteins in colon cancer cell lines with microsatellite instability. PLoS One 5: e16012.
22. Reuschenbach M, Kloor M, Morak M, Wentzensen N, Germann A, et al.(2009) Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome. Fam Cancer 9: 173-179.